We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00659971
First Posted: April 17, 2008
Last Update Posted: June 26, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Quintiles, Inc.
Information provided by:
Pacgen Biopharmaceuticals Corporation
March 18, 2008
April 17, 2008
June 26, 2008
January 2008
June 2008   (Final data collection date for primary outcome measure)
Eliminating or reducing clinical signs and symptoms of oral Candida infections. [ Time Frame: Day 19 ]
Same as current
Complete list of historical versions of study NCT00659971 on ClinicalTrials.gov Archive Site
To evaluate the microbiological response of Candida to different concentrations of PAC-113. [ Time Frame: Day 19 ]
Same as current
Not Provided
Not Provided
 
Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113
The purpose of this study is to determine the optimal dose of PAC113 mouthrinse for treatment of oral candidiasis in HIV seropositive patients.

This is a randomized, examiner-blinded, positive-controlled, parallel design clinical trial, which features 4 treatment arms. Forty-five (45)* HIV positive subjects per treatment arm will be recruited for 180 subjects total. The study includes 5 visits: a screening visit, a 14-day treatment phase with a baseline visit on Day 1, a Day 7 visit, a post-treatment visit 5 days after the last dose, and follow-up visit. During the screening visit subjects will be assessed for study eligibility. Eligible subjects will be randomized to 1 of the following treatment arms:

A. 0.15% PAC-113 mouthrinse (5 mL 4 times daily [q.i.d.]); B. 0.075% PAC-113 mouthrinse (5 mL q.i.d.); C. 0.0375% PAC-113 mouthrinse (5 mL q.i.d.); D. Nystatin oral suspension (100,000 units/mL; 5 mL q.i.d.) Subjects will be evaluated clinically for safety and severity of clinical signs and symptoms of oral candidiasis at baseline (Day 1), Day 7, Day 19 (5 days post-treatment) and Day 28 (follow-up visit). Subjects will also have a microbiological analysis performed at screening, and at Days 7, 19 and 28.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Oral Candidiasis
Drug: PAC113
PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
  • Experimental: 1
    PAC113 0,15% mouthrinse
    Intervention: Drug: PAC113
  • Experimental: 2
    PAC113 0,075% mouthrinse
    Intervention: Drug: PAC113
  • Experimental: 3
    PAC113 0,0375% mouthrinse
    Intervention: Drug: PAC113
  • Active Comparator: 4
    Nystatin suspension
    Intervention: Drug: PAC113
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
223
June 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Are male or female 18 to 65 years of age, inclusive
  • Are able and willing to follow study procedures and instructions
  • Are able to read, understand and sign an informed consent form
  • Are documented as HIV positive
  • Have pseudomembranous and/or erythematous oral candidiasis as confirmed by potassium hydroxide preparation of mucosal scraping
  • Have a CD4 cell count performed prior to randomization or within 6 weeks prior to the screening visit
  • Have a viral load performed prior to randomization or within 6 weeks prior to the screening visit.
  • Both men and women who are active heterosexually must be willing to practice a medically accepted method of birth control.

Exclusion Criteria:

  • Have received systemic antifungal therapy within 14 days of starting study
  • Have received prior topical therapy for oral candidiasis within 7 days of starting study
  • Have a concomitant fungal infection requiring systemic therapy
  • Are currently receiving immunosuppressive therapy (e.g. corticosteroids), or cancer chemotherapy
  • Female subjects who are pregnant (as determined by a positive serum or urine pregnancy test) or lactating, or female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control (e.g., oral or parenteral contraceptives, diaphragm plus spermicide, condoms) or who have not characterized themselves as abstinent. Subjects who use hormonal contraceptives must have started the method at least 30 days prior to the screening examination
  • Active substance abuse
  • Have esophageal symptoms (dysphagia or odynophagia) unless esophageal candidiasis has been ruled out by endoscopy
  • Have a life expectancy < 4 weeks
  • Are currently receiving or have received an investigational agent in the last 30 days
  • Have had a change in antiretroviral therapy within 14 days prior to study entry (this does not apply to dose adjustment of the same therapy)
  • Have any of the following laboratory abnormalities:

    • White blood cell (WBC) count <1,500 cells/mm3
    • Neutrophil granulocyte count <1,000 cells/mm3
    • Hemoglobin <9.0/dL
    • Transaminases (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) or bilirubin >3 times the upper limit of normal (ULN)
    • Serum creatinine >2 times ULN
  • Have peri-oral lesion (perleche) only
  • Have oral manifestations of herpes simplex (active disease only), hairy leukoplakia and/or aphthous ulcers
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00659971
PBC002-01
Yes
Not Provided
Not Provided
Pacgen Biopharmaceuticals Corp., Director, Drug Development
Pacgen Biopharmaceuticals Corporation
Quintiles, Inc.
Not Provided
Pacgen Biopharmaceuticals Corporation
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP